Allergic rhinitis
Conditions
Interventions
Desensitization therapy Group A:Artemisia was used 32 to 36 weeks before pollen season
Desensitization therapy Group B:Artemisia was used 20 to 24 weeks before pollen season
Desensitization therapy Group C:Artemisia was used 4 to 8 weeks before pollen season
Drug control group:Symptomatic treatment with antiallergic drugs
Sponsors
Beijing Shijitan Hospital affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: To enroll, patients must meet all of the following conditions: 1) Age 18-60 years old (including 18 years old and 60 years old), male or female; 2) Seasonal (summer and autumn) allergic rhinitis of 1 year or more, with or without conjunctivitis and asthma; 3) Serum specific IgE of Artemisia mugwort was positive and >= grade 2 (3.5 kU/L); 4) The patient can understand and sign the informed consent; 5) The patient agrees to comply with the protocol or is expected to comply with the protocol
Exclusion criteria
Exclusion criteria: Patients with any of the following conditions were excluded from the study: 1) Patients with oral diseases/oral allergies at the time of screening evaluation; 2) Patients who had received any surgery within four weeks before the screening evaluation; 3) Patients who systematically used systemic glucocorticoids within four weeks prior to the screening evaluation; 4) Patients who reviewed the period from July to October of the previous year and did not need to use oral antihistamines or nasal spray hormones to resolve rhinitis on their own; 5) Patients whose serological test results show that the specific IgE results of ragweed or humulus scandens are positive and the level reaches or exceeds the positive level of the specific IgE results of mugwort; 6) Patients with allergic rhinitis combined with asthma had a history of moderate or severe asthma from July to October of the previous year, and FEV1 was < 70% of the estimated value; Those who are being treated with beta-blockers (both systemic and topical); 7) Pregnant and lactating women, or have a pregnancy plan within the past year; 8) Patients with a history of immunosuppressive diseases (such as HIV infection), malignant tumors, autoimmune diseases, tuberculosis, cardiovascular insufficiency, or serious diseases of other organ systems judged by researchers;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of average daily rhinitis symptoms and symptomatic drug combinations situation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Compared to baseline daily average rhinitis symptom symptomatic medication combination situation;Compared to baseline daily average rhinitis symptom situation;Compared to baseline daily average symptomatic medication situation;Compared with baseline quality of life situation; | — |
Countries
China
Contacts
Public ContactTingting Ma
Beijing Shijitan Hospital affiliated to Capital Medical University
Outcome results
None listed